Skip to main content

Table 1 Demographics and baseline disease characteristics of csDMARD-IR patients included in the post hoc analysis

From: Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib

Demographic or baseline characteristica Tofacitinib 5 mg BID + csDMARDs (N = 742) Placebo + csDMARDs (N = 391)
Age (years), mean (range) 53.1 (18–86) 52.4 (18–81)
Female, n (%) 625 (84.2) 314 (80.3)
Smoking, n (%)
 Never smoked 511 (68.9) 260 (66.5)
 Smoker 96 (12.9) 74 (18.9)
 Ex-smoker 135 (18.2) 55 (14.1)
Duration of RA (years), mean (range) 8.0 (0.2–43.0) 8.8 (0.3–49.4)
DAS28-4(ESR) score, mean (SD) 6.4 (1.0) 6.3 (1.0)
TJC, mean (SD) 25.1 (14.7) 24.7 (14.0)
SJC, mean (SD) 14.8 (9.2) 14.8 (8.7)
ESR (mm/h), mean (SD) 50.1 (25.7) 50.2 (24.6)
RF-positive, n (%) 630 (84.9) 325 (83.1)
PtGA VAS score (mm), mean (SD) 58.3 (23.0) 55.0 (22.5)
Pain VAS score (mm), mean (SD) 57.7 (23.0) 55.2 (22.5)
HAQ-DI score, mean (SD) 1.4 (0.7) 1.3 (0.7)
FACIT-F score, mean (SD) 29.0 (10.7) 30.6 (10.2)
SF-36 PCS score, mean (SD) 33.1 (7.9) 33.7 (7.5)
SF-36 MCS score, mean (SD) 40.6 (11.9) 42.6 (11.5)
MDGA VAS score, mean (SD) 59.2 (16.9) 58.0 (16.9)
Concomitant therapy, n (%) 742 (100.0) 391 (100.0)
 Oral corticosteroids, n (%) 479 (64.6) 246 (62.9)
 Non-MTX csDMARDs, n (%) 152 (20.5) 75 (19.2)
 MTX, n (%) 677 (91.2) 354 (90.5)
 Concomitant MTX dose (mg), mean (range) 14.3 (1.4–25.0) 14.9 (1.0–25.0)
  1. Data presented for the full analysis set
  2. Abbreviations: BID twice daily, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-4(ESR) Disease Activity Score in 28 joints, ESR, ESR erythrocyte sedimentation rate, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire-Disability Index, IR inadequate responder, MCS Mental Component Summary, MDGA Physician Global Assessment of Arthritis, MTX methotrexate, PCS Physical Component Summary, PtGA Patient Global Assessment of Disease Activity, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, SF-36 36-item Short Form Health Survey, SJC swollen joint count, TJC tender joint count, VAS Visual Analog Scale
  3. an values for individual characteristics may vary